公开(公告)号：US20240360212A1

公开(公告)日：2024-10-31

申请号：US18766765

申请日：2024-07-09

Applicant: Janssen Biotech, Inc.

Inventor： Bruce Randazzo ,  Yasmine Wasfi

IPC: C07K16/24 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P17/06

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61P17/06 ,  C07K16/241 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565

Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

公开(公告)号：US20180094052A1

公开(公告)日：2018-04-05

申请号：US15719899

申请日：2017-09-29

Applicant: Janssen Biotech, Inc.

Inventor： Bruce Randazzo ,  Yasmine Wasfi

IPC: C07K16/24 ,  A61P17/06 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61P17/06 ,  C07K16/241 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565

Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.